###begin article-title 0
###xml 54 63 <span type="species:ncbi:7955">Zebrafish</span>
###xml 68 73 <span type="species:ncbi:9606">Human</span>
Mechanisms Underlying Metabolic and Neural Defects in Zebrafish and Human Multiple Acyl-CoA Dehydrogenase Deficiency (MADD)
###end article-title 0
###begin p 1
Conceived and designed the experiments: YS RJBG. Performed the experiments: YS MAS CTW CC PCS JAP SG MOS GW RGG DA MJB. Analyzed the data: YS RJBG. Wrote the paper: YS RJBG.
###end p 1
###begin p 2
###xml 339 345 339 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xavier</italic>
###xml 647 650 647 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 806 809 806 809 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 3 9 <span type="species:ncbi:9606">humans</span>
###xml 312 321 <span type="species:ncbi:7955">zebrafish</span>
###xml 378 386 <span type="species:ncbi:9606">patients</span>
In humans, mutations in electron transfer flavoprotein (ETF) or electron transfer flavoprotein dehydrogenase (ETFDH) lead to MADD/glutaric aciduria type II, an autosomal recessively inherited disorder characterized by a broad spectrum of devastating neurological, systemic and metabolic symptoms. We show that a zebrafish mutant in ETFDH, xavier, and fibroblast cells from MADD patients demonstrate similar mitochondrial and metabolic abnormalities, including reduced oxidative phosphorylation, increased aerobic glycolysis, and upregulation of the PPARG-ERK pathway. This metabolic dysfunction is associated with aberrant neural proliferation in xav, in addition to other neural phenotypes and paralysis. Strikingly, a PPARG antagonist attenuates aberrant neural proliferation and alleviates paralysis in xav, while PPARG agonists increase neural proliferation in wild type embryos. These results show that mitochondrial dysfunction, leading to an increase in aerobic glycolysis, affects neurogenesis through the PPARG-ERK pathway, a potential target for therapeutic intervention.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 299 302 299 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Knott1">[1]</xref>
###xml 304 307 304 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Mattson1">[2]</xref>
###xml 534 537 534 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Erecinska1">[3]</xref>
###xml 706 709 706 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Knott1">[1]</xref>
###xml 711 714 711 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Mattson1">[2]</xref>
###xml 716 719 716 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Wallace1">[4]</xref>
Mitochondria, the cellular power plants in most eukaryotic organisms, play pivotal roles in cell signaling, differentiation, and the control of cell cycle, growth and death. Particularly in the nervous system, mitochondrial function is essential in meeting the high energy demand in neurons and glia[1], [2]. During nervous system development, mitochondria regulate neural proliferation and differentiation by supporting the different bioenergetic requirements of highly proliferative neural stem cells compared to postmitotic neurons[3]. Mitochondrial dysfunction has been implicated in various aspects of neuronal and glial dysfunction, aging, as well as in the pathogenesis of neurodegenerative diseases[1], [2], [4]. However, how mitochondria cause and compensate for physiological and pathological challenges, and how this in turn affects neurogenesis, neural development, and nervous system function, remain poorly understood.
###end p 4
###begin p 5
###xml 252 255 252 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Frerman1">[5]</xref>
###xml 606 609 606 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Ruzicka1">[6]</xref>
###xml 611 614 611 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-McKean1">[7]</xref>
###xml 1078 1081 1078 1081 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Frerman1">[5]</xref>
Multiple acyl-CoA dehydrogenase deficiency (MADD), also known as glutaric aciduria type II, is an autosomal-recessive inherited disorder caused by mutations in electron transfer flavoprotein (ETF) or electron transfer flavoprotein dehydrogenase (ETFDH)[5]. In mitochondria, ETF, located in the matrix, receives electrons from several dehydrogenases involved in fatty acid oxidation, choline and amino acid metabolism. ETF then transfers electrons to ETFDH, located in the inner mitochondrial membrane, and subsequently, electrons are passed to ubiquinone in the respiratory chain, leading to ATP production[6], [7]. As a result of ETF or ETFDH deficiency, the acyl-CoA dehydrogenases are unable to transfer the electrons generated by dehydrogenation reactions, resulting in the accumulation of various intramitochondrial acyl-CoA esters. There is secondary accumulation of free acids, and other conjugation products (acylcarnitine and acylglycine esters) in blood and urine, including large amounts of the lysine metabolic intermediate glutaric acid, giving the disease its name[5].
###end p 5
###begin p 6
###xml 513 516 513 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Rinaldo1">[8]</xref>
###xml 545 548 545 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-VanHove1">[9]</xref>
###xml 550 554 550 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Bonham1">[10]</xref>
###xml 582 589 <span type="species:ncbi:9606">patient</span>
###xml 593 600 <span type="species:ncbi:9606">patient</span>
###xml 735 743 <span type="species:ncbi:9606">patients</span>
The clinical features of MADD are highly heterogeneous and have been classified as neonatal-onset form with (type I) or without (type II) congenital anomalies, and mild and/or late-onset form (type III). MADD consists of a large spectrum of symptoms, including hypotonia, hypoglycemia, cardiomyopathy, polycystic kidneys, and neurological manifestations such as symmetric warty dysplasia of the cerebral cortex, encephalopathy and leukodystrophy. While there have been case studies reporting the use of riboflavin[8] and sodium-3-hydroxybutyrate[9], [10] as treatment for MADD on a patient-by-patient basis, no systematic therapy has been validated. Moreover, despite the neurodevelopmental and cognitive dysfunction prominent in MADD patients, the anatomical, cellular and molecular abnormalities within the nervous system have not been well documented, and the mechanisms underlying neural phenotypes remain unexplored.
###end p 6
###begin p 7
###xml 90 93 90 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 124 127 124 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 213 217 213 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Panzer1">[11]</xref>
###xml 237 240 237 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 457 460 457 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 73 82 <span type="species:ncbi:7955">zebrafish</span>
###xml 389 394 <span type="species:ncbi:9606">human</span>
###xml 500 508 <span type="species:ncbi:9606">patients</span>
###xml 786 791 <span type="species:ncbi:9606">human</span>
Here we report the genetic, cellular and molecular characterization of a zebrafish mutant xav. We had previously identified xav as a mutant that exhibits abnormal motility and aberrant neuromuscular synaptogenesis[11]. We found that the xav mutation resides in ETFDH, which is critical for fatty acid, amino acid and choline metabolism. Because dysfunction of this gene is responsible for human MADD, we performed several cellular and molecular analyses on xav mutants and fibroblast cells from MADD patients. Our results advance our understanding of how metabolism affects neural development, link mitochondrial dysfunction and the resulting increase in aerobic glycolysis to neurogenesis via the PPARG-ERK pathway, and suggest this pathway as a target for therapeutic intervention in human MADD.
###end p 7
###begin title 8
Materials and Methods
###end title 8
###begin title 9
Ethics Statement
###end title 9
###begin p 10
###xml 4 13 <span type="species:ncbi:7955">zebrafish</span>
###xml 166 171 <span type="species:ncbi:9606">Human</span>
###xml 203 211 <span type="species:ncbi:9606">patients</span>
###xml 345 353 <span type="species:ncbi:9606">Children</span>
###xml 416 424 <span type="species:ncbi:9606">Children</span>
All zebrafish husbandry and experimentation were conducted under a protocol approved by the University of Pennsylvania's Institutional Animal Care and Use Committee. Human fibroblasts were obtained from patients after written informed consent was obtained from parents/next of kin, under a protocol approved by the Institutional Review Board of Children's Hospital of Wisconsin and the Institutional Review Board of Children's Hospital of Philadelphia.
###end p 10
###begin title 11
###xml 0 9 <span type="species:ncbi:7955">Zebrafish</span>
Zebrafish Husbandry
###end title 11
###begin p 12
###xml 68 71 68 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 103 107 103 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Panzer1">[11]</xref>
###xml 0 9 <span type="species:ncbi:7955">Zebrafish</span>
###xml 179 188 <span type="species:ncbi:7955">zebrafish</span>
Zebrafish were raised and maintained under standard conditions. The xav allele was previously described[11]. Wild type and mutant embryos were obtained from crosses between adult zebrafish.
###end p 12
###begin title 13
###xml 17 22 <span type="species:ncbi:9606">Human</span>
###xml 28 36 <span type="species:ncbi:9606">Patients</span>
Fibroblasts from Human MADD Patients
###end title 13
###begin p 14
###xml 566 570 566 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ETFA</italic>
###xml 865 869 865 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Schiff1">[36]</xref>
###xml 24 31 <span type="species:ncbi:9606">patient</span>
###xml 102 110 <span type="species:ncbi:9606">Children</span>
###xml 176 183 <span type="species:ncbi:9606">patient</span>
###xml 188 194 <span type="species:ncbi:9606">infant</span>
###xml 287 295 <span type="species:ncbi:9606">Children</span>
###xml 324 331 <span type="species:ncbi:9606">Patient</span>
###xml 534 541 <span type="species:ncbi:9606">patient</span>
###xml 657 664 <span type="species:ncbi:9606">patient</span>
###xml 794 801 <span type="species:ncbi:9606">patient</span>
###xml 1033 1041 <span type="species:ncbi:9606">patients</span>
###xml 1175 1183 <span type="species:ncbi:9606">Children</span>
###xml 1246 1254 <span type="species:ncbi:9606">Children</span>
Fibroblasts from a MADD patient 1, were obtained from Dr. William J. Rhead, Department of Pediatrics, Children's Hospital of Wisconsin. Fibroblasts from an age-matched control patient (an infant, <1 year of age, with no evident related disease) were obtained from Dr. Carsten Bonnemann, Children's Hospital of Philadelphia. Patient 1 is a deceased newborn with severe MADD, whose acylcarnitine profile showed elevations of C5- and C16- intermediates, and extremely low C2-carnitines (Dr. Rhead, personal communication). We found that patient 1showed mis-splicing of ETFA transcript, lacking the long isoform that contains exon2. Gene sequencing showed that patient 1 has a 52 C>T heterozygous mutation in exon2 that may cause the splicing defects. The same mutation has been reported in a MADD patient with neonatal neurological deterioration and metabolic acidosis[36]. Fibroblasts from passages 6 - 12 were grown to 80-100% confluency and used for metabolic or gene expression analyses as indicated. Fibroblasts were obtained from patients after written informed consent was obtained from parents/next of kin, under a protocol approved by the Institutional Review Board of Children's Hospital of Wisconsin and the Institutional Review Board of Children's Hospital of Philadelphia.
###end p 14
###begin title 15
Morpholino Injection
###end title 15
###begin p 16
###xml 68 73 68 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">etfdh</italic>
###xml 98 123 98 123 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">CTACCCCTGAAAACATTCAATTATA</named-content>
The morpholino antisense oligonucleotide (Gene Tools) targeting the etfdh intron2-exon3 junction (CTACCCCTGAAAACATTCAATTATA) was injected at the 1-2 cell stage at approximately8 ng.
###end p 16
###begin title 17
Plasma Acylcarnitine and Organic Acid Profiling
###end title 17
###begin p 18
###xml 241 245 241 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Shen1">[37]</xref>
###xml 463 467 463 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Bennett1">[38]</xref>
Sonicated fish (N = 40-80) were subjected to acylcarnitine and organic acid analysis. Acylcarnitines were analyzed by tandem mass spectrometry as butyl esters using the procedure initially developed for skin fibroblast acylcarnitine analysis[37]. Organic acids were analyzed as their trimethylsilyl derivatives by capillary gas chromatography- electron impact mass spectrometry using a procedure that was initially developed for urine and vitreous humour analysis[38].
###end p 18
###begin title 19
RNA Extraction and Quantitative RT-PCR (qRT-PCR)
###end title 19
###begin p 20
###xml 124 132 124 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008329.s003">Table S2</xref>
###xml 341 349 335 339 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;&#916;CT</sup>
###xml 382 393 372 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;-actin1</italic>
###xml 412 416 399 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACTB</italic>
###xml 398 407 <span type="species:ncbi:7955">zebrafish</span>
RNA was extracted from a pool of 20 embryos with the RNeasy kit (Qiagen). The primers for qRT-PCR are shown in Supplemental Table S2. qRT-PCR was performed with the SuperScript(R) III Platinum(R) SYBR(R) Green One-Step qPCR Kit w/ROX (Invitrogen) and data was analyzed with 7500 Real-Time PCR System software (Applied Biosystems) using the 2-DeltaCT method, data were normalized to beta-actin1 for zebrafish and ACTB for fibroblasts.
###end p 20
###begin title 21
BrdU Labeling and Immunostaining
###end title 21
###begin p 22
###xml 52 56 52 56 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Zannino1">[39]</xref>
###xml 431 435 413 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Panzer1">[11]</xref>
###xml 467 472 <span type="species:ncbi:10090">mouse</span>
###xml 529 535 <span type="species:ncbi:9986">rabbit</span>
BrdU labeling was performed as described previously [39]. In brief, at approximately56-60 hpf, embryos were incubated with 10 mM BrdU in 10% DMSO in embryo medium for 30 min. on ice and then raised in embryo medium at 28.5degreesC for 30 min. The embryos were then fixed using 4% paraformaldehyde in PBS, pH = 7.4, followed by 2 hour incubation in 2 M HCl. Embryos were anesthetized, fixed and immunostained as described previously[11] using antibodies against BrdU (mouse monoclonal Developmental Studies Hybridoma Bank (DSHB); rabbit polyclonal, Abcam) and dp-ERK (Sigma) and the appropriate fluorescently conjugated secondary antibody (Jackson Labs). Unless otherwise stated, each figure panel showing immunostaining is a single plane projection of a confocal z-stack of 20-60 1 microm thick planes (Leica TCS 4D system) and was assessed using interactive software (Metamorph).
###end p 22
###begin title 23
Western Blotting
###end title 23
###begin p 24
###xml 143 144 143 144 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
###xml 607 611 599 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Star</italic>
To prepare protein, embryos were triturated in lysis buffer (100 mM pH 8 Tris, 1% SDS, 10 mM EDTA, 50 mM DTT). Protein quantity was assessed (Dc Protein Assay; Bio-Rad) and proteins were separated by SDS-PAGE (4-10% gradient gel), transferred to a nitrocellulose membrane and probed with antibodies against AMPKalpha (Cell Signaling), phospho-AMPKalpha (Thr172) (Cell Signaling), PPARG (Santa Cruz), dp-ERK (Sigma), phospho-STAT3 (Tyr705) (MBL) and/or actin (Sigma). After washing, blots were incubated in AP-conjugated secondary antibody (Jackson Labs), and then visualized using chemiluminescence (WesternStar detection system; Applied Biosystems).
###end p 24
###begin title 25
ROS Labeling
###end title 25
###begin p 26
Embryos were incubated in embryo medium containing 10 microM of dyhydrorhodamine123 (DHR123, Invitrogen) for 2 hrs at 28degreesC, then washed with embryo medium several times and examined with confocal microscopy.
###end p 26
###begin title 27
PPARG Pharmacology
###end title 27
###begin p 28
###xml 59 63 55 59 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Wada1">[28]</xref>
###xml 96 100 88 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Nam1">[40]</xref>
Embryos were incubated in 25 micro m PPARG antagonist BADGE[28] or agonist 10 microM Ciglitizone[40] at approximately24 hpf until the desired developmental stage.
###end p 28
###begin title 29
Statistical Analyses
###end title 29
###begin p 30
All statistical analyses were performed with Prism software (Microcal) and Excel (Microsoft).
###end p 30
###begin title 31
Results
###end title 31
###begin title 32
###xml 65 68 65 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
External Phenotypes, Genetic Cloning and Morpholino Phenocopy of xav
###end title 32
###begin p 33
###xml 25 28 25 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 145 149 145 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Panzer1">[11]</xref>
###xml 163 166 163 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 339 352 339 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008329-g001">Figure 1A, 1B</xref>
We previously identified xav in a small scale genetic screen due to its abnormal swimming behavior and decreased number of neuromuscular synapses[11]. Externally, xav mutants cannot be distinguished from WT until after 48 hpf, when they start to exhibit a bent tail and slower heart beat, phenotypes that become progressively more severe (Figure 1A, 1B).
###end p 33
###begin title 34
###xml 66 69 66 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
External phenotype, genotype, cloning and morpholino phenocopy of xav mutants.
###end title 34
###begin p 35
###xml 0 2 0 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A.</bold>
###xml 12 15 12 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 20 25 20 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">etfdh</italic>
###xml 157 159 141 143 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B.</bold>
###xml 159 162 143 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 246 249 228 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 367 369 345 347 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C.</bold>
###xml 402 405 380 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 549 551 527 529 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D.</bold>
###xml 551 556 529 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">etfdh</italic>
###xml 569 572 547 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 754 756 732 734 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E.</bold>
###xml 779 782 757 760 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 836 841 814 819 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">etfdh</italic>
###xml 733 743 <span type="species:ncbi:238774|species:ncbi:386067|species:ncbi:147878|species:ncbi:193182|species:ncbi:313250|species:ncbi:323266|species:ncbi:315362|species:ncbi:148887|species:ncbi:124036|species:ncbi:48798|species:ncbi:529401|species:ncbi:314391|species:ncbi:646318|species:ncbi:254962|species:ncbi:323047|species:ncbi:287681|species:ncbi:269614|species:ncbi:103475|species:ncbi:114942|species:ncbi:212608|species:ncbi:457136|species:ncbi:227469|species:ncbi:449387|species:ncbi:551876|species:ncbi:248142|species:ncbi:252961|species:ncbi:466267|species:ncbi:119832|species:ncbi:228196|species:ncbi:316080|species:ncbi:217897|species:ncbi:109099|species:ncbi:328850|species:ncbi:266263|species:ncbi:348465|species:ncbi:181251|species:ncbi:6239|species:ncbi:320029|species:ncbi:293163|species:ncbi:4853|species:ncbi:160529|species:ncbi:292745|species:ncbi:368875|species:ncbi:323318|species:ncbi:209968|species:ncbi:405608|species:ncbi:480533">C. elegans</span>
###xml 747 752 <span type="species:ncbi:9606">human</span>
A. External xav and etfdh morphant (MO) phenotypes at approximately60 hpf include a bent and thinner tail and smaller head and eyes. Scale bar = 100 microm. B.xav mutants and MO exhibit slower heart beat (WT 158+/-6 beats/minute, N = 13 embryos; xav 87+/-7; N = 14 embryos; MO 65+/-7, N = 14 embryos; one-way ANOVA, followed by Dunn's pairwise comparison, * p<0.001. C. Genetic and physical map of the xav (zgc:92093) locus (red), including microsatellite and SSR markers, number of recombinants, and BAC clones from the T51 radiation hybrid panel. D.etfdh mutation in xav is a T to A mutation (blue box) resulting in a premature stop codon (red box). The amino acid sequence of etfdh is highly conserved among several species, from C. elegans to human. E. Schematic location of xav mutation, resulting in truncation of the C terminal. etfdh MO is predicted to give rise to a protein fragment lacking all functional domains.
###end p 35
###begin p 36
###xml 31 40 31 40 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008329.s004">Figure S1</xref>
###xml 47 55 47 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008329.s002">Table S1</xref>
###xml 68 71 68 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 92 101 92 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">zgc&#8758;92093</italic>
###xml 171 180 171 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008329-g001">Figure 1C</xref>
###xml 310 323 310 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008329-g001">Figure 1D, 1E</xref>
Positional cloning strategies (Figure S1; Sup. Table S1) identified xav mutation resides in zgc:92093, which encodes electron-transfer-flavoprotein dehydrogenase (etfdh) (Figure 1C). There is a T to A transversion at position 1305 which introduces a premature stop codon (Y435X) in the 617 amino acid protein (Figure 1D, 1E).
###end p 36
###begin p 37
###xml 52 61 52 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav etfdh</italic>
###xml 116 121 116 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">etfdh</italic>
###xml 130 133 130 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 237 242 237 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">etfdh</italic>
###xml 249 259 249 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008329.s005">Figure S2A</xref>
###xml 299 303 299 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Hentze1">[12]</xref>
###xml 318 321 318 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 589 599 589 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008329.s005">Figure S2B</xref>
###xml 629 632 629 632 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 680 685 680 685 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">etfdh</italic>
Besides the truncation of the protein caused by the xav etfdh mutation, we also found that the overall abundance of etfdh mRNA in xav is dramatically reduced. Real-time quantitative RT-PCR (qRT-PCR) showed that there is 80% reduction of etfdh mRNA (Figure S2A), likely due to nonsense mediated decay[12]. Furthermore, xav mutants showed nonsense mediated alternative splicing. As a result of the mutation, which resides in exon11, the exon10-exon13 junctions are mis-spliced in mutants, resulting in transcripts that are predicted to encode proteins lacking critical domains or truncated (Figure S2B). These results suggest that xav contains a likely loss of function mutation in etfdh.
###end p 37
###begin p 38
###xml 19 24 19 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">etfdh</italic>
###xml 48 51 48 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 102 107 102 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">etfdh</italic>
###xml 180 185 180 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">etfdh</italic>
###xml 367 377 367 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008329.s006">Figure S3C</xref>
###xml 379 381 379 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008329-g003">3D</xref>
###xml 456 465 456 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008329-g001">Figure 1E</xref>
###xml 468 473 468 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">etfdh</italic>
###xml 534 547 534 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008329-g001">Figure 1A, 1B</xref>
###xml 663 670 663 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008329.s001">Text S1</xref>
###xml 672 681 672 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008329.s009">Figure S6</xref>
###xml 710 713 710 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 728 736 728 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008329.s013">Video S1</xref>
###xml 743 751 743 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008329.s014">Video S2</xref>
###xml 782 787 782 787 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">etfdh</italic>
###xml 816 819 816 819 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
To confirm whether etfdh is the gene mutated in xav, we designed a splice-blocking morpholino against etfdh and compared the phenotypes in morphants and mutants. Injection of 8 ng etfdh MOI2E3 in WT embryos, which targets intron2-exon 3 junction, results in >80% reduction of the normal transcript at 2 and 3 dpf, producing a mis-spliced transcript that lacks exon3 (Figure S3C, 3D), resulting in predicted protein fragment lacking all functional domains (Figure 1E). etfdh morphants not only showed bent tail and reduced heart beat (Figure 1A, 1B), but also exhibited aberrant swimming behavior and reduced neuromuscular synaptogenesis (see Supplemental Results Text S1; Figure S6; and data not shown), as in xav mutants (Sup. Video S1; Sup. Video S2). These results indicate that etfdh mutation is responsible for xav phenotypes.
###end p 38
###begin title 39
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 92 100 <span type="species:ncbi:9606">Patients</span>
xav Mutants Exhibit Plasma Acylcarnitine and Organic Acid Profiles Similar to Those in MADD Patients
###end title 39
###begin p 40
###xml 20 23 20 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 91 94 91 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 325 328 325 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 33 41 <span type="species:ncbi:9606">patients</span>
###xml 147 152 <span type="species:ncbi:9606">human</span>
###xml 153 161 <span type="species:ncbi:9606">patients</span>
Given the fact that xav and MADD patients have mutation in the same gene, we asked whether xav mutants exhibit phenotypes similar to those seen in human patients. Clinically, MADD is diagnosed by the plasma acylcarnitine profile, the urine organic acid profile and acylglycine analysis. These analyses were thus performed in xav mutants compared to WT embryos.
###end p 40
###begin p 41
###xml 139 142 139 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 251 260 251 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008329-g002">Figure 2A</xref>
###xml 397 400 394 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 443 446 440 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Frerman1">[5]</xref>
###xml 435 443 <span type="species:ncbi:9606">patients</span>
Tandem mass spectroscopy of plasma acylcarnitine detected a markedly higher level of a spectrum of intermediate acyl-fatty acid species in xav mutants, including C4, C5, C6, C8, C14, C16 and C18, together with a drastic reduction of C2 acylcarnitine (Figure 2A), suggesting dysregulation of mitochondrial beta-oxidation and alterations in multiple intermediary mitochondrial metabolic pathways in xav, similar to that observed in MADD patients[5].
###end p 41
###begin title 42
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Xav</italic>
Xav mutants display abnormal acylcarnitine and organic acid profile.
###end title 42
###begin p 43
###xml 0 2 0 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A.</bold>
###xml 67 70 67 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 201 204 201 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 333 336 321 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 376 378 352 354 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B.</bold>
###xml 442 445 418 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 585 588 561 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 649 652 613 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
A. Representative acylcarnitine profile from homogenates of WT and xav mutant embryos using tandem mass spectrometry, showing a markedly higher level of several intermediate acyl-fatty acid species in xav mutants including C4, C5, C6, C8, C14, C16 and C18, and a reduction of C2 acetylcarnitine (pool of approximately100 embryos for xav mutant and WT at approximately56 hpf). B. Representative organic acid profile from homogenates of WT and xav mutant embryos using gas chromatography electron impact mass spectrometric analysis, showing an elevation of the level of glutaric acid in xav mutants (black arrow) (pool of approximately100 embryos for xav mutant and WT at approximately56 hpf).
###end p 43
###begin p 44
###xml 120 123 120 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 125 134 125 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008329-g002">Figure 2B</xref>
###xml 196 199 196 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 308 311 300 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Frerman1">[5]</xref>
###xml 300 308 <span type="species:ncbi:9606">patients</span>
Gas chromatographic analysis of organic acids from embryo homogenates detected a dramatic elevation of glutaric acid in xav (Figure 2B). Further quantification showed the glutaric acid content in xav is 0.99 microg/embryo, but <0.05 microg/embryo in WT, resembling the glutaric acidemia seen in MADD patients[5].
###end p 44
###begin p 45
###xml 124 127 124 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 395 398 395 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 454 463 442 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008329.s006">Figure S3</xref>
###xml 587 592 575 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">etfdh</italic>
###xml 605 608 593 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 70 78 <span type="species:ncbi:9606">patients</span>
###xml 288 297 <span type="species:ncbi:7955">zebrafish</span>
###xml 302 308 <span type="species:ncbi:9606">humans</span>
###xml 538 546 <span type="species:ncbi:9606">patients</span>
While acylglycine analysis showed elevated acylglycine levels in MADD patients, no acylglycine was detected in either WT or xav embryos. This suggests that the function of glycine-N-acyltransferase, which converts acyl-CoA and glycine to CoA and acylglycine, may not be conserved between zebrafish and humans. Moreover, kidney defects were observed at the organ structural and cellular level in xav mutants compared to WT embryos at approximately60 hpf (Figure S3), consistent with a polycystic kidney phenotype that is prominent in MADD patients. Together, these analyses show that the etfdh mutation in xav results in MADD like metabolic and kidney defects.
###end p 45
###begin title 46
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
xav Mutants Exhibit Several Hallmarks of Mitochondrial Dysfunction
###end title 46
###begin p 47
###xml 11 16 11 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">etfdh</italic>
###xml 170 173 170 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 268 271 268 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 333 334 321 322 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 498 505 482 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008329.s001">Text S1</xref>
###xml 543 544 527 528 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 595 598 567 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 643 652 615 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008329-g003">Figure 3A</xref>
###xml 654 664 626 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008329.s007">Figure S4A</xref>
###xml 711 714 683 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 729 739 701 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008329.s007">Figure S4A</xref>
###xml 798 801 770 773 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
Given that etfdh functions in mitochondria, and is involved in electron transport from fatty acid and amino acids, we asked whether mitochondrial function is abnormal in xav mutants. First, we evaluated the respiratory and phosphorylation activities in homogenates of xav mutants and WT embryos at approximately56 hpf, by measuring O2 consumption in the presence of alpha-ketoglutarate or fatty acids (palmitoylcarnitine and octoylcarnitine) as substrates (see Supplemental Experimental Procedures Text S1). ADP-stimulated (state 3) rates of O2 consumption were decreased approximately30-35% in xav mitochondria with each of these substrates (Figure 3A; Figure S4A). The blunted rates of state 3 respiration in xav mitochondria (Figure S4A) suggest that oxidative phosphorylation is compromised in xav mutants.
###end p 47
###begin title 48
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
xav mutants exhibit mitochondrial dysfunction.
###end title 48
###begin p 49
###xml 0 2 0 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A.</bold>
###xml 189 192 185 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 295 298 275 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 408 411 384 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 483 485 459 461 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B.</bold>
###xml 642 645 614 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 730 733 686 689 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 852 855 806 809 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 940 942 892 894 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C.</bold>
###xml 953 954 905 906 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1018 1021 970 973 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 1086 1089 1026 1029 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 1174 1178 1112 1116 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D&#8211;E.</bold>
###xml 1250 1253 1188 1191 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 1302 1308 1236 1242 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Thr172</sup>
###xml 1391 1394 1325 1328 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 1452 1455 1386 1389 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 1531 1533 1463 1465 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F.</bold>
###xml 1598 1601 1518 1521 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 1669 1672 1587 1590 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 1773 1775 1689 1691 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G.</bold>
###xml 1923 1929 1827 1833 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mt-nd5</italic>
###xml 1934 1940 1838 1844 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ndufs1</italic>
###xml 2008 2017 1900 1906 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pgc-1&#946;</italic>
###xml 2019 2028 1908 1913 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">esrr&#945;</italic>
###xml 2033 2042 1918 1923 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ppar&#947;</italic>
###xml 2046 2049 1927 1930 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 2098 2118 1979 1999 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">uncoupling protein 4</italic>
###xml 2120 2125 2001 2006 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fucp4</italic>
###xml 2182 2186 2051 2055 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ucp2</italic>
###xml 2292 2294 2161 2163 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H.</bold>
###xml 2448 2451 2317 2320 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 2564 2566 2429 2431 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I.</bold>
###xml 2703 2711 2556 2564 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">catalase</italic>
###xml 2760 2781 2601 2622 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">glutathione reductase</italic>
###xml 2786 2791 2627 2632 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hspa9</italic>
###xml 2795 2798 2636 2639 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 2088 2097 <span type="species:ncbi:7955">zebrafish</span>
A. Measured rates of state 3 respiration supported by oxidation of alpha-ketoglutarate and fatty acids (palmitoylcarnitine and octoylcarnitine (each + malate)) showed a 30-35% reduction in xav mutant compared to WT embryos at approximately56 hpf (values normalized to WT; alpha-ketoglutarate in xav, 0.72+/-0.10; N = 4 experiments 50-100 embryos each; Student's t test, * p = 0.03; fatty acid 0.65+/-0.10 in xav; N = 4 experiments 50-100 embryos each; Student's t test, * p = 0.02). B. Membrane potential generated by oxidation of alpha-ketoglutarate and fatty acids was estimated using TMRE and spectrofluorometry, showing a 55% increase in xav compared to WT at approximately56 hpf (values normalized to WT; alpha-ketoglutarate xav 1.55 +/- 0.15; N = 4 experiments 50-100 embryos each; Student's t test, *** p<0.001) and a 50% reduction (fatty acids xav 0.53+/-0.07; N = 5 experiments 50-100 embryos each; Student's t test, *** p<0.001). C. Measured O2 consumption rates with ascorbate/TMPD showed a 40% increase in xav compared to WT at approximately56 hpf (values normalized to WT; xav 1.39+/-0.13; N = 6 experiments 50-100 embryos each; Student's t test, * p = 0.014). D-E. Western blot showed that while the total level of AMPK is unchanged in xav, the amount of activated AMPK (phospho-AMPKalphaThr172) protein is significantly increased. Quantification showed a 2.3 fold increase in xav mutants compared to WT embryos (values normalized to WT; xav 2.3+/-0.6; N = 3 experiments 30 embryos each; Student's t test, * p<0.05). F. Levels of ATP production showed a approximately45% reduction in xav mutants compared to WT embryos (WT 20.6+/-2.6 nmol per mg protein; xav 11.3+/-2.3 nmol per mg protein; N = 9 replicates, 50-100 embryos each, Student's t test, * p<0.05). G. mRNA levels of genes involved in mitochondrial function and biogenesis were analyzed with qRT-PCR. A approximately30-40% reduction was observed in mt-nd5 and ndufs1, and a approximately2.4, 1.5 and 2.8 fold increase was observed in pgc-1beta, esrralpha and ppargamma in xav mutants compared to WT. Expression of zebrafish uncoupling protein 4 (fucp4) was increased approximately6 fold, while expression of ucp2 was unchanged (N = 3-4 replicates, 20 embryos each; Student's t test, * p<0.05, ** p<0.01, *** p<0.001). H. The oxidative fluorescent dye DHR-123 was used to measure cellular superoxide production in live embryos and showed higher cellular superoxide levels in xav mutants compared to WT, especially in the nervous system, including in the spinal cord. Scale bar = 100 microm. I. Expression profile of genes known to be involved in the ROS pathway was assayed with qRT-PCR and showed a approximately50% reduction of catalase transcripts and approximately5 fold increase of glutathione reductase and hspa9 in xav compared to WT (N = 3 replicates, 20 embryos each; Student's t test, * p<0.05, ** p<0.01).
###end p 49
###begin p 50
###xml 346 348 346 348 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 493 496 493 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 899 908 875 884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008329-g003">Figure 3B</xref>
###xml 962 963 938 939 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1067 1068 1043 1044 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1118 1121 1090 1093 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 1207 1216 1167 1176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008329-g003">Figure 3B</xref>
###xml 1408 1411 1364 1367 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
Mitochondria establish a transmembrane potential, which is generated when the energy released by the flow of electrons through the electron transport chain is used to pump protons out of the mitochondrial inner membrane through complexes I, III, and IV, and is utilized to support critical cellular processes, such as the production of ATP and Ca2+ uptake. We estimated mitochondrial membrane potential using the positively charged fluorescent probe tetramethylrhodamine ethyl ester (TMRE) in xav mutant and WT embryos at approximately56 hpf. Mitochondrial transmembrane was estimated as the difference in fluorescence signals following substrate energization and complete depolarization and collapse of the membrane potential following addition of uncoupler. We found a approximately50% reduction of membrane potential generated by oxidation of fatty acid (palmitoylcarnitine and octoylcarnitine) (Figure 3B), consistent with the observed decreases in state 3 O2 consumption with these substrates. Surprisingly, however, despite the decrease in the rate of state 3 O2 consumption observed with alpha-ketoglutarate in xav, mitochondrial membrane potential was estimated to be increased by approximately50% (Figure 3B). This result suggests that the transmembrane potential generated when alpha-ketoglutarate is oxidized by the electron transport chain may not be properly utilized for ADP phosphorylation in xav mutants.
###end p 50
###begin p 51
###xml 34 35 34 35 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 122 125 118 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 275 284 271 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008329-g003">Figure 3C</xref>
###xml 376 379 372 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 525 528 509 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 553 563 537 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008329.s007">Figure S4B</xref>
Despite reduced rates of state 3 O2 consumption observed following the oxidation of alpha-ketoglutarate and fatty acid in xav, the activity of complex IV was increased by 40% when assayed directly after addition of ascorbate/N,N,N',N'-tetramethyl-p -phenylenediamine (TMPD) (Figure 3C), suggesting a possible compensatory metabolic response to augment respiratory capacity in xav mutants. Consistent with this idea, at approximately56 hpf, a higher level of F1-F0 ATPase (complex V) protein was detected by immunostaining in xav mutants compared to WT (Figure S4B). This likely reflects an adaptation to insufficient respiration, and is consistent with compensation.
###end p 51
###begin p 52
###xml 762 765 762 765 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 813 819 809 815 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Thr172</sup>
###xml 857 870 853 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008329-g003">Figure 3D, 3E</xref>
###xml 936 939 932 935 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 1069 1072 1053 1056 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 1104 1113 1088 1097 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008329-g003">Figure 3F</xref>
###xml 1252 1257 1236 1241 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">etfdh</italic>
###xml 1270 1273 1254 1257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
To further assess mitochondrial defects, we examined the activity of AMP-activated protein kinase (AMPK), which is an evolutionarily conserved metabolic sensor that responds to alterations in cellular energy levels to maintain energy balance. AMPK activation occurs in response to ATP depletion and a concomitant increase in the AMP/ATP ratio. Once activated, AMPK phosphorylates numerous downstream substrates thereby initiating a series of responses aimed at restoring cellular energy balance by switching off ATP-consuming, anabolic pathways, such as fatty acid synthesis and protein synthesis and switching on ATP-generating pathways such as fatty acid oxidation and glycolysis. Biochemical analyses showed that while the total level of AMPK is unchanged in xav, the level of activated AMPK (phospho-AMPKalphaThr172) protein is significantly increased (Figure 3D, 3E). This result suggests that there is a homeostatic regulation in xav mutants, in response to alterations in metabolism. In addition, measurement of ATP levels showed a approximately45% reduction in xav mutant compared to WT embryos (Figure 3F), despite a compensatory increase of complex IV, complex V and activated, p-AMPK protein levels. Together, these results suggest that the etfdh mutation in xav results in metabolic reprogramming, which is not restricted to and cannot fully compensate for the defect in the fatty acid oxidation.
###end p 52
###begin p 53
###xml 68 71 68 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 225 234 225 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008329-g003">Figure 3G</xref>
###xml 281 287 269 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mt-nd5</italic>
###xml 292 298 280 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ndufs1</italic>
###xml 563 567 551 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Benit1">[13]</xref>
###xml 569 573 557 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Loeffen1">[14]</xref>
###xml 575 579 563 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Triepels1">[15]</xref>
###xml 599 608 587 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pgc-1&#946;</italic>
###xml 610 619 595 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">esrr&#945;</italic>
###xml 624 633 605 610 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ppar&#947;</italic>
###xml 806 826 771 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">uncoupling protein 4</italic>
###xml 828 833 793 798 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fucp4</italic>
###xml 1033 1037 986 990 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ucp2</italic>
###xml 1094 1099 1047 1052 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fucp4</italic>
###xml 1111 1115 1064 1068 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UCP3</italic>
###xml 1169 1173 1122 1126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Russell1">[16]</xref>
###xml 1273 1276 1226 1229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 1300 1305 1253 1258 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">etfdh</italic>
###xml 796 805 <span type="species:ncbi:7955">zebrafish</span>
###xml 1103 1109 <span type="species:ncbi:9606">humans</span>
###xml 1161 1169 <span type="species:ncbi:9606">patients</span>
In order to gain more insight into the mitochondrial dysfunction in xav and the underlying molecular mechanisms, we profiled the expression of genes known to be involved in mitochondrial function and biogenesis with qRT-PCR (Figure 3G). We found a approximately30-40% reduction of mt-nd5 and ndufs1, two mitochondria encoded genes that belong to complex I. Mutations of these genes are associated with complex I deficiency and mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), two disorders which have neurological manifestations[13], [14], [15]. The expression of pgc-1beta, esrralpha and ppargamma, genes involved in transcriptional regulation of energy metabolism, were increased approximately2.4, 1.5 and 2.8 fold, respectively. Interestingly, expression of zebrafish uncoupling protein 4 (fucp4), which is proposed to be responsible for uncoupling of respiration from ATP synthesis and thus protect against reactive oxygen species (ROS) production, showed a approximately6 fold increase, while ucp2 expression remained unchanged. The closest homologue of fucp4 in humans, UCP3, has been reported to be upregulated in MADD patients[16]. These results document mitochondrial dysfunction at the level of alteration of gene expression in xav mutants as a result of etfdh mutation.
###end p 53
###begin p 54
###xml 104 108 101 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Wallace2">[17]</xref>
###xml 348 351 345 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 440 449 437 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008329-g003">Figure 3H</xref>
###xml 585 593 582 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">catalase</italic>
###xml 629 650 626 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">glutathione reductase</italic>
###xml 652 661 649 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008329-g003">Figure 3I</xref>
###xml 754 759 751 756 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hspa9</italic>
###xml 761 770 758 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008329-g003">Figure 3I</xref>
###xml 833 837 830 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Craven1">[18]</xref>
###xml 874 879 871 876 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">etfdh</italic>
###xml 961 964 958 961 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 1063 1066 1056 1059 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 1470 1471 1463 1464 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1490 1494 1483 1487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Murphy1">[19]</xref>
###xml 1496 1500 1489 1493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-AdamVizi1">[20]</xref>
Impairment of mitochondrial metabolism, including beta-oxidation, may result in greater oxidative stress[17], which increases generation of ROS. The oxidative fluorescent dye dihydrorodamine-123 (DHR-123) was used to qualitatively address cellular superoxide production. DHR-123 labeling in live embryos showed higher cellular superoxide levels in xav mutants compared to WT, especially in the nervous system, including in the spinal cord (Figure 3H). We next assessed the expression profile of genes known to be involved in the ROS pathway. qRT-PCR analyses showed a 50% reduction of catalase transcripts and 5-fold increase of glutathione reductase (Figure 3I), both of which are known to function in ROS scavenging. We also found a 5 fold increase of hspa9 (Figure 3I), mutation of which produces an increase in ROS in blood cells[18]. These results further confirm that etfdh mutation results in mitochondrial dysfunction and subsequent oxidative stress in xav mutants. Moreover, the increased membrane potential observed with alpha-ketoglutarate + malate in xav, as discussed above, may also contribute to the increased ROS production. Mitochondrial ROS formation is favored by a high transmembrane potential: increased membrane potential decreases electron flow and decreased electron flow in turn increases the half-life of partially reduced components of the electron transport chain, thereby increasing the probability these carriers may donate an electron to O2 to form superoxide[19], [20].
###end p 54
###begin title 55
###xml 73 76 73 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human MADD Fibroblast Cells Display Similar Mitochondrial Dysfunction as xav Mutants
###end title 55
###begin p 56
###xml 66 69 66 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 99 107 <span type="species:ncbi:9606">patients</span>
###xml 129 136 <span type="species:ncbi:9606">patient</span>
###xml 244 251 <span type="species:ncbi:9606">Patient</span>
###xml 269 276 <span type="species:ncbi:9606">patient</span>
We next asked whether the mitochondrial abnormalities observed in xav are similar to those in MADD patients. As analyses of MADD patient tissues are rare, and postmortem tissues are not available, we performed analyses on fibroblast cells from Patient 1, and a control patient.
###end p 56
###begin p 57
###xml 141 142 141 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</italic>
###xml 206 215 206 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008329-g004">Figure 4A</xref>
###xml 300 303 300 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 517 524 517 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 878 887 878 887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008329-g004">Figure 4B</xref>
###xml 981 984 981 984 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 1057 1065 1057 1065 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1121 1128 1121 1128 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 17 24 <span type="species:ncbi:9606">Patient</span>
###xml 379 386 <span type="species:ncbi:9606">Patient</span>
###xml 855 862 <span type="species:ncbi:9606">Patient</span>
###xml 966 974 <span type="species:ncbi:9606">patients</span>
Fibroblasts from Patient 1 exhibited markedly increased uncontrolled mitochondrial respiration as elicited by the uncoupler carbonyl cyanide m-chlorophenylhydrazone (CICCP) compared to control fibroblasts (Figure 4A), resembling the increased complex IV activity and complex V expression observed in xav. The observation that uncoupler-stimulated respiration in fibroblasts from Patient 1 was so significantly above the basal respiratory rate suggests that proton translocation through the mitochondrial ATP synthase in situ limits state 3 oxygen consumption, and therefore ATP synthesis, in these cells. The addition of uncoupler relieves/removes any constraint on respiration which may be imposed by proton movement through the ATP synthase, thereby increasing respiration to a maximal level. Basal ATP levels were slightly but significantly reduced in Patient 1 fibroblasts (Figure 4B). These results suggest altered respiratory capacity and compensation in MADD patients as in xav mutants. Moreover, while electron transport chain is compromised, cells in vitro are more readily able to maintain ATP homeostasis than in vivo, either by upregulating reserve respiratory capacity, by shifting to glycolysis (as discussed in the following section) or by reducing dependence on fatty acids.
###end p 57
###begin title 58
###xml 69 72 69 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human MADD fibroblast cells display similar mitochondrial defects as xav mutants.
###end title 58
###begin p 59
###xml 0 2 0 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A.</bold>
###xml 693 695 685 687 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B.</bold>
###xml 880 882 872 874 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C.</bold>
###xml 932 941 924 930 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PGC-1&#946;</italic>
###xml 943 948 932 937 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 950 959 939 944 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESRR&#945;</italic>
###xml 961 965 946 950 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UCP3</italic>
###xml 1145 1153 1118 1126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">catalase</italic>
###xml 1187 1208 1160 1181 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">glutathione reductase</italic>
###xml 1213 1218 1186 1191 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HSPA9</italic>
###xml 62 69 <span type="species:ncbi:9606">Patient</span>
###xml 447 454 <span type="species:ncbi:9606">Patient</span>
###xml 757 764 <span type="species:ncbi:9606">Patient</span>
###xml 1020 1027 <span type="species:ncbi:9606">Patient</span>
###xml 1107 1114 <span type="species:ncbi:9606">Patient</span>
A. Oxygen consumption was measured in intact control and MADD Patient 1 fibroblasts under basal conditions, following the addition of the mitochondrial ATP synthase inhibitor oligomycin (0.5 microg/ml), in the presence of the uncoupler CICCP (3 microM) to maximally stimulate respiration and following the addition of complex I inhibitor rotenone (100 nM) to assess residual non-mitochondrial oxygen consumption. A 2-fold increase was observed in Patient 1 fibroblasts compared to control, after uncoupler CICCP treatment, which measures the maximal uncontrolled mitochondrial respiratory capacity (N = 3 experiments, 7-9 replicates of cells from passage 7-12; Student's t test, *** p<0.001). B. Measurement of ATP levels showed a ca. 10% reduction in MADD Patient 1 fibroblast cells compared to control (N = 14 replicates of cells from passage 7-12; Student's t test, * p<0.05). C. Gene expression assayed by qRT-PCR revealed that PGC-1beta, PPARG, ESRRalpha, UCP3 were increased approximately2, 4.6, 2 and 1.6 fold in Patient 1 compared to control. The expression of ROS related genes are also altered in Patient 1, with a ca. 20% decrease in catalase and 4.7 and 5.7 fold increase in glutathione reductase and HSPA9 expression (N = 3-7 replicates of cells from passage 7-12; Student's t test, * p<0.05, ** p<0.01, *** p<0.001).
###end p 59
###begin p 60
###xml 40 49 40 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PGC-1&#946;</italic>
###xml 51 56 48 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 58 67 55 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESRR&#945;</italic>
###xml 69 73 62 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UCP3</italic>
###xml 121 130 114 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008329-g004">Figure 4C</xref>
###xml 139 142 132 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 230 233 223 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 259 267 252 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">catalase</italic>
###xml 282 303 275 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">glutathione reductase</italic>
###xml 308 313 301 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HSPA9</italic>
###xml 315 324 308 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008329-g004">Figure 4C</xref>
###xml 520 523 513 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 110 117 <span type="species:ncbi:9606">Patient</span>
###xml 213 220 <span type="species:ncbi:9606">Patient</span>
###xml 412 417 <span type="species:ncbi:9606">human</span>
###xml 533 541 <span type="species:ncbi:9606">patients</span>
###xml 643 648 <span type="species:ncbi:9606">human</span>
Gene expression profiling revealed that PGC-1beta, PPARG, ESRRalpha, UCP3 were all significantly increased in Patient 1 (Figure 4C), as in xav. Furthermore, the expression of ROS related genes are also altered in Patient 1, as in xav, in particular decreased catalase and increased glutathione reductase and HSPA9 (Figure 4C). These results extend our understanding of the extent of mitochondrial dysfunction in human MADD, and show further that this dysfunction is similar at the metabolic and gene expression level in xav and MADD patients. Furthermore, this indicates that the dysfunction is independent of the particular gene resulting in human MADD, as both ETF and ETFDH defects demonstrate similar abnormalities in these studies.
###end p 60
###begin title 61
###xml 21 24 21 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
MADD Fibroblasts and xav Mutants Exhibit Increased Aerobic Glycolysis
###end title 61
###begin p 62
###xml 237 246 237 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008329-g005">Figure 5A</xref>
###xml 422 426 422 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Watanabe1">[21]</xref>
###xml 810 819 798 807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008329-g005">Figure 5B</xref>
###xml 971 980 959 968 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">enolase 1</italic>
###xml 982 986 970 974 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENO1</italic>
###xml 989 1014 977 1002 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">phosphoglycerate mutase 1</italic>
###xml 1016 1021 1004 1009 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PGAM1</italic>
###xml 1024 1049 1012 1037 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">phosphoglycerate kinase 1</italic>
###xml 1051 1055 1039 1043 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PGK1</italic>
###xml 1061 1080 1049 1068 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">phosphofructokinase</italic>
###xml 1082 1086 1070 1074 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PFKM</italic>
###xml 1139 1148 1127 1136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008329-g005">Figure 5C</xref>
###xml 170 177 <span type="species:ncbi:9606">Patient</span>
###xml 458 465 <span type="species:ncbi:9606">Patient</span>
###xml 689 696 <span type="species:ncbi:9606">Patient</span>
###xml 1129 1137 <span type="species:ncbi:9606">patients</span>
###xml 1235 1243 <span type="species:ncbi:9606">patients</span>
During the course of measuring mitochondrial oxidative responses, we noticed that there was also a significant increase in the extracellular acidification rate (ECAR) in Patient 1 fibroblasts, especially in the presence of an uncoupler (Figure 5A). ECAR reflects changes in proton concentration and is used as readout of lactate production as this dominates the acidification and is thus used as a surrogate for glycolysis[21]. While the increase in ECAR in Patient 1 fibroblasts suggested that aerobic glycolysis is increased, we performed two additional analyses to further examine this possibility. First, the amount of lactate secreted into the culture medium was directly measured in Patient 1 fibroblasts. Basal lactate production was increased by approximately25%, consistent with increased glycolysis (Figure 5B). Second, the expression profile of genes critical for glycolysis or in the glycolytic pathway was assessed using qRT-PCR. mRNA for glycolytic enzymes enolase 1 (ENO1), phosphoglycerate mutase 1 (PGAM1), phosphoglycerate kinase 1 (PGK1) and phosphofructokinase (PFKM) were all significantly increased in MADD patients (Figure 5C). These results suggest that aerobic glycolysis is increased in fibroblasts from MADD patients.
###end p 62
###begin title 63
###xml 53 56 53 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
Increased aerobic glycolysis in MADD fibroblasts and xav mutants.
###end title 63
###begin p 64
###xml 0 2 0 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A.</bold>
###xml 582 584 574 576 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B.</bold>
###xml 826 828 806 808 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C.</bold>
###xml 904 913 884 893 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">enolase 1</italic>
###xml 915 919 895 899 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENO1</italic>
###xml 922 947 902 927 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">phosphoglycerate mutase 1</italic>
###xml 949 954 929 934 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PGAM1</italic>
###xml 957 982 937 962 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">phosphoglycerate kinase 1</italic>
###xml 984 988 964 968 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PGK1</italic>
###xml 994 1013 974 993 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">phosphofructokinase</italic>
###xml 1015 1019 995 999 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PFKM</italic>
###xml 1225 1227 1193 1195 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D.</bold>
###xml 1286 1289 1242 1245 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 1415 1417 1359 1361 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E.</bold>
###xml 1506 1510 1450 1454 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eno1</italic>
###xml 1512 1518 1456 1462 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pgam1a</italic>
###xml 1520 1524 1464 1468 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pgk1</italic>
###xml 1526 1531 1470 1475 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pfkma</italic>
###xml 1537 1568 1481 1512 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fructose-biphosphate aldolase C</italic>
###xml 1570 1575 1514 1519 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">aldoc</italic>
###xml 1663 1699 1595 1631 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dihydrolipoamide S-acetyltransferase</italic>
###xml 1701 1705 1633 1637 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dlat</italic>
###xml 1821 1824 1753 1756 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 48 55 <span type="species:ncbi:9606">Patient</span>
###xml 447 454 <span type="species:ncbi:9606">Patient</span>
###xml 693 700 <span type="species:ncbi:9606">Patient</span>
###xml 1096 1103 <span type="species:ncbi:9606">Patient</span>
A. ECAR was measured in intact control and MADD Patient 1 fibroblasts under basal conditions, following the addition of the mitochondrial inhibitor oligomycin (0.5 microg/ml), in the presence of the uncoupler CICCP (3 microM) and following the addition of the complex I inhibitor rotenone (100 nM). A trend towards higher ECAR rate was seen under basal conditions, and a significant 2-fold increase was observed after uncoupler CICCP treatment in Patient 1 fibroblasts compared to control. (N = 3 experiments, 7-9 replicates of cells from passage 7-12; Student's t test, * p<0.05). B. Lactate present in the culture medium showed a approximately20% increase in the basal lactate production in Patient 1 fibroblasts compared to control (N = 2 experiments, 5-6 replicates of cells from passage 7-8; Student's t test, * p<0.05). C. qRT-PCR analyses of genes involved in glycolysis showed glycolytic enzymes enolase 1 (ENO1), phosphoglycerate mutase 1 (PGAM1), phosphoglycerate kinase 1 (PGK1) and phosphofructokinase (PFKM), were increased by approximately1.9, 2.7, 3.4 and 3.1 fold respectively in Patient 1 fibroblasts compared to control (N = 5 replicates of cells from passage 7-9; Student's t test, * p<0.05, *** p<0.001). D. Lactate levels showed a approximately2.4 fold increase in xav mutants compared to WT embryos at approximately56 hpf (N = 7-9 replicates, 30-100 embryos each; Student's t test, * p<0.05). E. qRT-PCR analyses of gene expression revealed increased expression of glycolytic enzymes eno1, pgam1a, pgk1, pfkma, and fructose-biphosphate aldolase C (aldoc) by 2.8, 2, 1.9, 1.8 and 2.1 fold respectively, as well a approximately20% decrease in dihydrolipoamide S-acetyltransferase (dlat), that belongs to the pyruvate dehydrogenase complex, which links glycolysis to tricarboxylic acid (TCA) cycle, in xav mutants compared to WT embryos at approximately56 hpf (N = 3-7 replicates, 20 embryos each; Student's t test, * p<0.05, ** p<0.01).
###end p 64
###begin p 65
###xml 52 55 52 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 167 170 155 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 226 235 202 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008329-g005">Figure 5D</xref>
###xml 378 382 354 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eno1</italic>
###xml 384 390 360 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pgam1a</italic>
###xml 392 396 368 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pgk1</italic>
###xml 401 406 377 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pfkma</italic>
###xml 419 450 395 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fructose-biphosphate aldolase C</italic>
###xml 452 457 428 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">aldoc</italic>
###xml 488 497 464 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008329-g005">Figure 5E</xref>
###xml 509 545 485 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dihydrolipoamide S-acetyltransferase</italic>
###xml 547 551 523 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dlat</italic>
###xml 698 707 674 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008329-g005">Figure 5E</xref>
###xml 773 776 749 752 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 1092 1096 1068 1072 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dlat</italic>
###xml 1100 1103 1076 1079 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 752 757 <span type="species:ncbi:9606">human</span>
To determine whether glycolysis is also elevated in xav mutants, the amount of lactate was directly measured and was found to be increased by approximately2.4 fold in xav mutants compared to WT embryos at approximately56 hpf (Figure 5D). Gene expression analyses by qRT-PCR revealed significant changes in expression of several glycolytic genes. mRNA for the glycolytic enzymes eno1, pgam1a, pgk1 and pfkma, as well as fructose-biphosphate aldolase C (aldoc) was significantly increased (Figure 5E). mRNA for dihydrolipoamide S-acetyltransferase (dlat), that belongs to the pyruvate dehydrogenase complex (PDH) which links glycolysis to tricarboxylic acid (TCA) cycle, was significantly decreased (Figure 5E). Together, these data suggest that in both human MADD cells and xav mutants, the defect in fatty acid oxidation compromises oxidative phosphorylation, leading to an upregulation in aerobic glycolysis as an alternative energy source, possibly as a consequence of AMPK activation, in an attempt to compensate for this metabolic insuffiency. Furthermore, the decreased expression in of dlat in xav will likely result in decreased activity of PDH, in turn diverting pyruvate away from mitochondria, decreasing flux through the Krebs cycle and thereby decreasing delivery of reducing equivalents in the form of NADH to the electron transport chain. Shunting of pyruvate away from mitochondria would thus contribute to the conversion of glucose to lactate and further exacerbate any underlying defects in the electron transport chain by restricting oxidation of a very important mitochondrial substrate, favoring a glycolytic phenotype.
###end p 65
###begin title 66
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
xav Mutants Exhibit Increased Neural Proliferation
###end title 66
###begin p 67
###xml 369 373 369 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-VanderHeiden1">[22]</xref>
###xml 562 565 562 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 771 778 771 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008329.s001">Text S1</xref>
###xml 783 792 783 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008329.s008">Figure S5</xref>
###xml 794 796 794 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008329.s009">S6</xref>
###xml 798 800 798 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008329.s010">S7</xref>
###xml 802 804 802 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008329.s011">S8</xref>
###xml 806 808 806 808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008329.s012">S9</xref>
###xml 870 873 870 873 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
Many proliferating cells, including some cancer cells, utilize aerobic glycolysis, which while an inefficient way to generate ATP compared to oxidative phosphorylation, has been suggested to have the advantage of generating a number of biosynthetic intermediates which can be used to incorporate nutrients into the cell biomass, a phenomenon known as the Warburg effect[22]. Because a shift away from oxidative phosphorylation to an increased dependence upon aerobic glycolysis may affect proliferation, and because of the striking neural phenotypes observed in xav mutants, including reduced neuropil staining, abnormal glial patterning, reduced motor axon branching and neuromuscular synaptogenesis, increased cell death and progressive paralysis (Supplemental Results Text S1 and Figure S5, S6, S7, S8, S9), we asked whether neural cell proliferation is increased in xav mutants compared to WT embryos using BrdU incorporation.
###end p 67
###begin p 68
###xml 122 125 122 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 171 184 171 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008329-g006">Figure 6A, 6B</xref>
###xml 333 336 297 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 485 494 449 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008329-g006">Figure 6A</xref>
###xml 607 611 571 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Mueller1">[23]</xref>
###xml 613 617 577 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Mueller2">[24]</xref>
###xml 715 718 679 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
The number of BrdU+ cells was significantly increased throughout the nervous system, in particular in the spinal cord, of xav mutants compared to WT embryos at 56-60 hpf (Figure 6A, 6B). While in approximately56-60 hpf WT embryos, there are approximately3 BrdU+ cells in the spinal cord per hemisegment, there are approximately24 in xav mutant embryos at the same developmental stage, resulting in an expansion of the proliferating cellular domain dorso-ventrally and rostro-caudally (Figure 6A). The peri-ventricular location of these BrdU+ cells suggests that they are likely to be neural progenitor cells[23], [24]. These observations suggest that neural cell proliferation is increased in the nervous system of xav mutants.
###end p 68
###begin title 69
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
xav mutants exhibit increased neural cell proliferation as a result of increased glycolysis, due to perturbation of the PPARG-ERK pathway.
###end title 69
###begin p 70
###xml 0 2 0 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A.</bold>
###xml 192 195 192 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 339 342 327 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 401 403 377 379 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B.</bold>
###xml 439 442 415 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 691 693 651 653 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C.</bold>
###xml 818 821 764 767 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 860 863 802 805 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 904 907 842 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 981 984 915 918 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 1063 1065 995 997 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D.</bold>
###xml 1166 1169 1094 1097 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 1284 1286 1200 1202 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E.</bold>
###xml 1370 1373 1286 1289 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 1416 1419 1328 1331 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 1661 1664 1549 1552 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 1675 1679 1561 1565 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav </italic>
A. Whole mount embryos labeled with BrdU to mark cells undergoing proliferation. The number of BrdU+ cells was significantly increased in the nervous system, especially in the spinal cord, in xav mutants compared to WT embryos at approximately56-60 hpf. Increased dp-ERK+ cells and BrdU+/dp-ERK+ double labeled cells in the spinal cord in xav mutants compared to WT embryos at approximately56-60 hpf. B. In spinal cord cross-sections from xav mutants and WT embryos at approximately56-60 hpf, BrdU+ cells are distributed peri-ventricularly, suggesting that they are likely to be neural progenitor cells. Dashed line outlines the spinal cord and indicates the midline. Scale bar = 20 microm. C. Quantification of BrdU+ and dp-ERK+ cells at approximately56-60 hpf. Per spinal cord hemisegment: BrdU+ cells WT 3.2+/-0.4, xav 24+/-1.4; dp-ERK+ cells WT 2.6+/-0.3, xav 19.4+/-0.8; BrdU+/dp-ERK+ WT 0.2+/-0.2, xav 7.8+/-1.2. Percent of BrdU+ cells that are also dp-ERK+: WT 3.6%+/-3.6%, xav 45%+/-8% (N = 4-19 embryos, >2 carrier pairs; Student's t test, *** p<0.001). D. Western blot analyses of ppargamma, dp-ERK and phospho-STAT3 expression showed dramatic increase in xav compared to WT embryos at approximately56-60 hpf (N = 3 replicates, 30 embryos each; Student's t test, * p<0.05). E. BrdU labeling of proliferating cells in whole mounts of spinal cord of WT embryos, xav mutants, WT treated with 25 microm BADGE, xav mutants treated with 25 microm BADGE and WT treated with 10 microm Ciglitizone at approximately56-60 hpf. Embryos were raised in BADGE or Ciglitizone from 24 to 60 hpf. Per spinal hemisegment: BrdU+ cells WT 3.2+/-0.4, WT + BADGE 4.5+/-0.3, xav 24+/-1.4, xav + BAGDE 10.6+/-0.9, WT + Ciglitizone 36+/-2.5 (N = 6-19 embryos, >3 carrier pairs; one-way ANOVA, followed by Bonferroni's multiple comparison test, *** p<0.001).
###end p 70
###begin title 71
###xml 104 107 104 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
Relationship between Increased Activation of the PPAR-ERK Pathway and Increased Neural Proliferation in xav Mutants
###end title 71
###begin p 72
###xml 117 120 117 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 303 307 303 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Fajas1">[25]</xref>
###xml 470 474 470 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Braissant1">[26]</xref>
###xml 476 480 476 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Moreno1">[27]</xref>
###xml 546 554 546 554 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 595 599 595 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Wada1">[28]</xref>
###xml 660 665 660 665 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 680 683 680 683 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 285 290 <span type="species:ncbi:9606">human</span>
###xml 373 378 <span type="species:ncbi:10090">mouse</span>
###xml 459 464 <span type="species:ncbi:10090">mouse</span>
###xml 708 715 <span type="species:ncbi:9606">patient</span>
In order to explore the mechanistic relationship between metabolic dysfunction and increased neural proliferation in xav, we focused on the PPARG-ERK pathway. PPARG is a known regulator of the cell cycle and apoptosis, and is highly expressed in many cells, including neurons and some human cancer cells[25]. High levels of PPARG expression have been reported in embryonic mouse brain and neural progenitors, while very low levels have been reported in adult mouse brain[26], [27]. Recently, PPARG has been shown to regulate neural proliferation in vitro, through the activation of ERK and STAT3[28]. Because our qRT-PCR analyses showed a dramatic increase in PPARG expression in xav mutant embryos and MADD patient fibroblasts, this pathway was further examined using Western blot and immunostaining analyses.
###end p 72
###begin p 73
###xml 72 75 72 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 119 128 119 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008329-g006">Figure 6D</xref>
###xml 258 262 258 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Neumann1">[29]</xref>
###xml 387 390 387 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 441 454 429 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008329-g006">Figure 6A, 6D</xref>
###xml 518 521 506 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 712 715 664 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 758 771 698 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008329-g006">Figure 6A, 6C</xref>
###xml 978 984 918 924 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Tyr705</sup>
###xml 985 989 925 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Yamashita1">[30]</xref>
###xml 1065 1068 1005 1008 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 1078 1087 1018 1027 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008329-g006">Figure 6D</xref>
###xml 1159 1162 1099 1102 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
Western blot analyses showed that PPARG protein levels were elevated in xav, consistent with elevated mRNA expression (Figure 6D). Western blot and immunostaining analyses were also used to assess ERK activation using a phospho-ERK specific antibody (dp-ERK)[29]. The amount of dp-ERK protein was significantly increased, and dp-ERK immunoreactivity was increased in the spinal cord, of xav compared to WT embryos at approximately56-60 hpf (Figure 6A, 6D). BrdU labeling of dividing cells and dp-ERK immunostaining in xav mutant embryos at approximately56-60 hpf revealed a significant increase in the number of double positive BrdU+/dp-ERK+ cells, from approximately0 in WT to approximately8 per hemisegment in xav mutant embryos at approximately56-60 hpf (Figure 6A, 6C). Furthermore, 45% of the BrdU+ cells were dp-ERK positive. Western blot analyses were then used to assess the level of activated STAT3 protein, using an antibody against phosphorylated STAT3 (phospho-STAT3Tyr705)[30]. The amount of phosphorylated STAT3 protein was significantly increased in xav embryos (Figure 6D). These results suggest that the PPARG-ERK pathway is dysfunctional in xav mutants, and is associated with increased cell proliferation.
###end p 73
###begin p 74
###xml 159 162 159 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 418 421 414 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 494 503 466 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008329-g006">Figure 6E</xref>
###xml 718 727 674 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008329-g006">Figure 6E</xref>
###xml 830 833 786 789 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 968 977 900 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008329-g006">Figure 6F</xref>
###xml 1009 1016 941 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008329.s001">Text S1</xref>
PPARG antagonists and agonists were used to assess the mechanistic relationship between the PPARG-ERK pathway and the increased cell proliferation observed in xav mutant embryos. We found that 25 microM of the PPARG antagonist 2,2-Bis[4-(glycidyloxy)phenyl]propane, 4,4'-isopropylidenediphenol diglycidyl ether (BADGE), when applied from 24-60 hpf, significantly reduced the number of BrdU+cells in the spinal cord of xav mutants, from approximately24 to approximately10 cells per hemisegment (Figure 6E). Furthermore, 10 microM of the PPARG agonist Ciglitizone, when applied to WT embryos from 24-60 hpf, significantly increased cell proliferation in the spinal cord, from approximately3 to 36 cells per hemisegment (Figure 6E). Moreover, we found that BADGE, when applied from 24-60 hpf, significantly reduced the proportion of xav mutants that were paralyzed at approximately60 hpf, from 18% to 4%, and also delayed the onset of paralysis by approximately12 hours (Figure 6F; see also Supplemental Results Text S1).
###end p 74
###begin p 75
###xml 176 179 176 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 329 332 329 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 350 358 <span type="species:ncbi:9606">patients</span>
Together, these data suggest that aberrant activation of the PPARG-ERK pathway underlies, at least in part, the cell proliferation and behavioral defects that are prominent in xav mutants, linking metabolic and mitochondrial dysfunction with defects in nervous system development, and possibly other organ system development, in xav mutants and MADD patients.
###end p 75
###begin title 76
Discussion
###end title 76
###begin p 77
###xml 19 22 19 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 111 114 111 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 369 372 369 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 541 544 541 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 597 600 597 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 1096 1099 1096 1099 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 165 172 <span type="species:ncbi:9606">patient</span>
We report that the xav mutation causes a loss of ETFDH function and defective electron transfer, and that both xav and fibroblasts from a phenotypically severe MADD patient have similar metabolic defects and mitochondrial dysfunction, including altered energy metabolism, dysregulated ROS production and altered expression of genes critical for mitochondrial function. xav mutants and MADD fibroblasts exhibit increased aerobic glycolysis, similar to the Warburg effect observed in cancer cells, leading to excessive neural proliferation in xav, mediated by upregulation of the PPARG-ERK pathway. xav mutants also display motility defects culminating in paralysis, abnormal glial patterning, reduced motor axon branching and neuromuscular synapse number, but muscle fiber and neuromuscular synapse function appear normal. While there is increased apoptosis throughout the nervous system, many of these phenotypes are independent of cell death, as they are not rescued when cell death is blocked. Strikingly, a PPARG antagonist attenuates aberrant neural proliferation and alleviates paralysis in xav, while PPARG agonists increase neural proliferation in wild type embryos. This work provides further insights into the relationship between metabolism and neural development, specifically that mitochondrial dysfunction leads to an increase in aerobic glycolysis which affects neurogenesis, at least in part through the PPARG-ERK pathway.
###end p 77
###begin p 78
###xml 523 527 523 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Brown1">[31]</xref>
While it is not surprising that mutations in ETF genes or ETFDH would lead to impaired fatty acid, choline and amino acid metabolism, it is interesting that a broader metabolic defect is also present. Our finding that mitochondrial oxidative phosphorylation stimulated by substrates other than fatty acids is also compromised, and that there is a compensatory elevation of complex IV activity, complex V expression and glycolysis further supports the idea that there is crosstalk between bioenergetic and metabolic pathways[31].
###end p 78
###begin p 79
###xml 482 486 482 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-VanderHeiden1">[22]</xref>
###xml 733 736 733 736 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 990 993 990 993 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
In most cancer cells and other rapidly proliferating cell populations, ATP is produced primarily by aerobic glycolysis followed by lactate fermentation, rather than by mitochondrial oxidative phosphorylation as in normal, differentiated cells, a phenomenon known as the Warburg effect. The Warburg effect has been proposed as an adaptive strategy to facilitate the uptake and incorporation of essential biosynthetic intermediates needed for increasing cell biomass and proliferation[22]. Despite understanding that proliferating cells switch from oxidative phosphorylation to aerobic glycolysis, the underlying triggers, effectors and mediators of this switch remain elusive. We show using several cellular and molecular assays that xav mutants and MADD fibroblasts exhibit a similar switch characterized by enhanced aerobic glycolysis accompanied by reduced mitochondrial oxygen consumption, the consequence of which is increased cell proliferation, in particular in the nervous system of xav mutants.
###end p 79
###begin p 80
###xml 161 164 161 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ETF</italic>
###xml 168 173 168 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ETFDH</italic>
###xml 183 186 183 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Frerman1">[5]</xref>
###xml 349 353 349 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Bohm1">[32]</xref>
###xml 355 359 355 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Shevell1">[33]</xref>
###xml 361 365 361 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Takanashi1">[34]</xref>
###xml 367 371 367 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Stockler1">[35]</xref>
###xml 376 379 376 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 731 734 731 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 1024 1027 1024 1027 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 1068 1071 1068 1071 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
While the molecular basis of the metabolic pathology in MADD can be explained by the malfunction of fatty acid, choline and amino acid metabolism as a result of ETF or ETFDH mutation [5], it remains unclear why individuals with MADD exhibit other defects, especially neurological defects including cortex dysplasia, encephalopathy and leukodystrophy[32], [33], [34], [35]. In xav mutants, the deficiency of fatty acid metabolism and oxidative phosphorylation may force cells to augment glycolysis as an alternative energy source for energy and biosynthetic intermediates to preserve viability. This switch may alter the balance between cell proliferation and differentiation, a major regulator of which is PPARG signaling. In both xav mutants and MADD fibroblasts, PPARG expression is increased at the mRNA and protein level, and activation of downstream effectors such as ERK and STAT3 are also increased. We showed that PPARG elevation underlies, in large part, the increase in cell proliferation in the nervous system of xav mutants by antagonizing this pathway in xav and agonizing this pathway in WT embryos. Under physiological conditions, the PPARG pathway may act as a sensor of the balance between oxidative phosphorylation and aerobic glycolysis, and shift the balance between neural cell proliferation and differentiation accordingly.
###end p 80
###begin p 81
###xml 6 9 6 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 155 158 155 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 198 203 198 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">etfdh</italic>
###xml 669 672 669 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008329-Frerman1">[5]</xref>
###xml 861 864 861 864 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 902 905 902 905 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 139 144 <span type="species:ncbi:9606">human</span>
###xml 780 788 <span type="species:ncbi:9606">patients</span>
###xml 874 881 <span type="species:ncbi:9606">patient</span>
###xml 974 979 <span type="species:ncbi:9606">human</span>
###xml 985 993 <span type="species:ncbi:9606">patients</span>
Using xav as a model for MADD, we have gained new insights into the cellular and molecular mechanisms underlying this rare but devastating human disorder. xav is the first animal model in which the etfdh gene is affected and in which neural defects can be demonstrated and studied. We have also identified the PPARG-ERK pathway as potentially valuable for therapeutic intervention. Understanding the relationship between metabolic and mitochondrial deficiencies and the mechanisms underlying the pathology of MADD, in particular the neurological phenotypes, has been hampered by the rarity of the disorder and thus analyses of autopsy and other tissues has been limited[5]. It will be of particular interest to assess neural cell proliferation and other neural phenotypes in MADD patients as tissues become available. The striking phenotypic similarity between xav and MADD patient cells suggests that xav mutants will be a useful discovery tool to guide future analyses in human MADD patients, and identify avenues for therapeutic intervention.
###end p 81
###begin title 82
Supporting Information
###end title 82
###begin p 83
Supplemental Results and Methods
###end p 83
###begin p 84
(0.10 MB DOC)
###end p 84
###begin p 85
Click here for additional data file.
###end p 85
###begin p 86
###xml 25 34 <span type="species:ncbi:7955">zebrafish</span>
Primer sequences for new zebrafish simple sequence repeat (SSR) markers.
###end p 86
###begin p 87
(0.03 MB DOC)
###end p 87
###begin p 88
Click here for additional data file.
###end p 88
###begin p 89
###xml 51 54 51 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 76 81 <span type="species:ncbi:9606">human</span>
###xml 87 95 <span type="species:ncbi:9606">patients</span>
Primers for qRT-PCR analyses of gene expression in xav and fibroblasts from human MADD patients.
###end p 89
###begin p 90
(0.08 MB DOC)
###end p 90
###begin p 91
Click here for additional data file.
###end p 91
###begin p 92
###xml 19 22 19 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 69 72 69 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 106 109 106 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 86 91 <span type="species:ncbi:9606">human</span>
Genetic map of the xav locus. Conserved synteny between genes in the xav interval and human chromosome 4. xav linkage results suggest the sequence in and around BAC clone DKEY-50I13 (accession no. CR846102.12) is misplaced on the Ensembl Zv6 genome build.
###end p 92
###begin p 93
(0.46 MB EPS)
###end p 93
###begin p 94
Click here for additional data file.
###end p 94
###begin p 95
###xml 70 75 70 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">etfdh</italic>
###xml 90 93 90 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 124 129 124 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">etfdh</italic>
###xml 208 213 196 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">etfdh</italic>
###xml 222 225 210 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 308 311 296 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 346 349 334 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 686 689 674 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 813 818 801 806 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">etfdh</italic>
###xml 841 846 829 834 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">etfdh</italic>
Nonsense mediated decay and nonsense mediated alternative splicing of etfdh transcript in xav, and morpholino knock down of etfdh. A. qRT-PCR showed that there is a significant, approximately80% reduction of etfdh mRNA in xav, likely due to nonsense mediated decay. N = 3 pools of 20 embryos each for WT and xav; Student's t test, * p<0.0001. B. xav mutants showed nonsense mediated alternative splicing. As a result of the mutation, which resides in exon11, the exon10-exon13 junctions are mis-spliced in mutants, resulting in transcripts that are predicted to encode proteins lacking critical domains or truncated. Blue arrows indicate primer location. These results suggest that the xav mutation is likely to be loss of function. C. A splice-blocking morpholino against intron2-exon3 (MOI2E3) was designed for etfdh. D. Injection of 8 ng etfdh MOI2E3 in WT embryos, results in >80% reduction of the normal transcript at 2 and 3 dpf, producing a mis-spliced transcript that lacks exon3. Red arrow indicates the MO location and blue arrows indicate primer location.
###end p 95
###begin p 96
(0.44 MB EPS)
###end p 96
###begin p 97
Click here for additional data file.
###end p 97
###begin p 98
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 285 288 285 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 510 513 494 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 85 94 <span type="species:ncbi:7955">zebrafish</span>
xav mutants display polycystic kidney like phenotypes. Immunostaining of whole mount zebrafish embryos revealed that the cilia in the pronephric ducts, as labeled by immunostaining with anti-acetylated tubulin antibody, appear distended and irregularly thickened, and contain gaps, in xav mutants compared to WT embryos at approximately60 hpf. Pronephric duct epithelial cells, as labeled by immunostaining with the anti-NaK ATPase antibody alpha6F, appear irregular in shape and showed aberrant clustering in xav embryos. N = >10 xav and WT embryos for each immunostaining assessment. Scale bar = 20 microm.
###end p 98
###begin p 99
(0.39 MB EPS)
###end p 99
###begin p 100
Click here for additional data file.
###end p 100
###begin p 101
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 77 78 77 78 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 117 120 117 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 175 178 175 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 236 237 236 237 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 562 563 558 559 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 674 675 670 671 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 913 916 897 900 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 1181 1184 1165 1168 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 1246 1249 1230 1233 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
xav mutants exhibit respiratory deficiency. A. Polarographic traces showing O2 consumption by mitochondria in WT and xav homogenates. Freshly prepared homogenates from WT and xav embryos were incubated in an oxygen sensor chamber, and O2 consumption (y axis) as a function of incubation time (x axis) was recorded. In the upper panels, homogenates were incubated with alpha-ketoglutarate + malate, and in the lower panels, homogenates were incubated with fatty acid (C16 carnitine + malate). Maximal rates of electron transfer were determined from the rates of O2 consumption driven by ADP (0.2 mM) and inorganic phosphate (state 3) and state 4 determined from the rate of O2 consumption upon conversion of the ADP to ATP. N = >10 embryos from at least 2 carrier pairs for each metabolic assay. B. At approximately56 hpf, a higher level of F1-F0 ATPase (complex V) protein was detected by immunostaining (red) in xav mutants (lower panels) compared to WT embryos (upper panels). A higher magnification view of the spinal cord is shown in the right most panels. TUNEL staining (green) was performed simultaneously and showed that there is increased cell death in the spinal cord in xav and that complex V positive cells are also TUNEL positive in xav. N = >10 embryos from at least 2 carrier pairs for each immunostaining assay. Scale bar = 100 microm.
###end p 101
###begin p 102
(0.89 MB EPS)
###end p 102
###begin p 103
Click here for additional data file.
###end p 103
###begin p 104
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 71 74 71 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
xav mutants exhibit neural and glial defects and cell death. At 3 dpf, xav embryos exhibited increased cell death as assayed by TUNEL staining (green), reduced neuropil as assayed by SV2 staining (blue). Glia number and patterning as assayed by GFAP staining (red) was aberrant throughout the nervous system. Not only were glial processes irregular in shape, but clumps of GFAP+cells were observed in several brain regions (white arrowheads point to several examples). N>3 embryos, 1 carrier pair. Scale bar = 20 microm.
###end p 104
###begin p 105
(0.33 MB EPS)
###end p 105
###begin p 106
Click here for additional data file.
###end p 106
###begin p 107
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 270 273 270 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 286 291 286 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">etfdh</italic>
###xml 428 435 424 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 482 485 478 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
xav mutants exhibit reduced motor axon branching and neuromuscular synaptogenesis that are not caused by change of motor neuron number or viability. A. SV2 (green) and AChR (red) labeling showed that motor axon branching and neuromuscular synaptogenesis were reduced in xav mutants and etfdh morphants compared to WT embryos, at 56 hpf and most strikingly at 72 hpf. Scale bar = 20 microm. B. Motor neuron number, as assayed by in situ hybridization for islet-2, is similar between xav mutants and WT embryos at 48 hpf. Scale bar = 100 microm. C. No substantial apoptosis was seen in the pool of motor neurons in xav compared to WT at 48 hpf, as assayed by double staining for TUNEL and Zn5, which labels secondary motor neurons. N>10 embryos, 3 carrier pairs. Scale bar = 20 microm.
###end p 107
###begin p 108
(0.38 MB EPS)
###end p 108
###begin p 109
Click here for additional data file.
###end p 109
###begin p 110
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 530 533 522 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
xav mutants display electrophysiological properties in the muscle, comparable to WT. A-C. Miniature excitatory postsynaptic current (mEPC) recordings from fast muscles showed a significant reduction in the mEPC rise time (WT 0.122+/-0.007 ms, xav 0.096+/-0.002 ms, N = 6, Student's t test, * p<0.05) and the frequency (WT 0.36+/-0.07 Hz, xav 0.10+/-0.05 Hz, N = 6; Student's t test, * p<0.05), but no statistical difference in terms of amplitude and exponential decay time. N = 6-8 embryos, 2 carrier pairs. D. Muscle fibers from xav embryos fire action potentials after exogenous stimulation, comparable in amplitude and shape to action potentials recorded from muscle fibers from WT embryos. There is no significant difference in terms of action potential amplitude, threshold or half width. N = 5 embryos, 2 carrier pairs.
###end p 110
###begin p 111
(4.62 MB EPS)
###end p 111
###begin p 112
Click here for additional data file.
###end p 112
###begin p 113
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 366 369 354 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 78 82 <span type="species:ncbi:262676">Mito</span>
xav mutants exhibit aberrant mitochondria distribution in motor neurons. A-B. Mito-GFP was expressed in motor neurons and branching and synapse formation followed over time. In WT embryos at approximately56 hpf, mitochondria are distributed along the entire axon. Mitochondria are continuously added over time, increasing both in number and density. In contrast, in xav mutants, while the number and distribution of mitochondria clusters along the axon are comparable to WT embryos at approximately56 hpf, the continuous addition of mitochondria is absent, resulting in a decrease of mitochondria cluster density by 3 dpf. N = 9-10 embryos, 3-4 carrier pairs. Scale bar = 20 microm.
###end p 113
###begin p 114
(0.51 MB EPS)
###end p 114
###begin p 115
Click here for additional data file.
###end p 115
###begin p 116
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 202 205 202 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 338 341 338 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 638 641 626 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
xav mutants exhibit cell death throughout the nervous system that is rescued by p53 morpholino knockdown and does not account for the motor axon branching, neuromuscular synapse or motility defects. A. xav mutants exhibit widespread cell death in the peripheral and central nervous system. There was a dramatic increase in TUNEL+cells in xav mutants compared to WT embryos at approximately56-72 hpf, particularly in the retina and spinal cord. B. At 56 hpf, cell death was blocked using a morpholino against p53. However, blocking cell death did not block the reduction of axon branching and synaptogenesis phenotypes that are present in xav mutants. N>6 embryos, 2 carrier pairs. Scale bar = 100 microm.
###end p 116
###begin p 117
(0.39 MB EPS)
###end p 117
###begin p 118
Click here for additional data file.
###end p 118
###begin p 119
###xml 107 110 107 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 48 57 <span type="species:ncbi:7955">zebrafish</span>
Spontaneous movements and motility in wild type zebrafish embryos at 48 hpf. The motility of wild type and xav mutant embryos were examined using high-speed video microscopy at 48 hpf. Wild type embryos spend most of the time staying still when not stimulated, and exhibit quick, darting movements when they swim.
###end p 119
###begin p 120
(3.98 MB AVI)
###end p 120
###begin p 121
Click here for additional data file.
###end p 121
###begin p 122
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 118 121 118 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
###xml 196 199 196 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xav</italic>
xav mutants exhibit increased spontaneous movement but with reduced motility at 48 hpf. The motility of wild type and xav mutant embryos were examined using high-speed video microscopy at 48 hpf. xav mutants show increased spontaneous twitching when not stimulated, and exhibit reduced motility when they swim, often exhibiting spasmodic like movements.
###end p 122
###begin p 123
(4.91 MB AVI)
###end p 123
###begin p 124
Click here for additional data file.
###end p 124
###begin p 125
###xml 263 266 263 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hb9</italic>
###xml 49 56 <span type="species:ncbi:9606">patient</span>
###xml 114 121 <span type="species:ncbi:9606">patient</span>
###xml 189 193 <span type="species:ncbi:262676">mito</span>
###xml 614 623 <span type="species:ncbi:7955">zebrafish</span>
We thank Dr. William J. Rhead for providing MADD patient fibroblasts, Dr. Carsten Bonnemann for providing control patient fibroblasts, Drs. Marnie Halpern and Bill Saxton for providing the mito-GFP construct, Drs. Michael Granato and Dirk Meyer for providing the hb9 construct, Drs. S. Nona and J. Scholes for providing the anti-GFAP antibody, Dr. Ethan Hughes for assisting with quantification of neuromuscular synapses, Dr. Ang Li for assistance with qRT-PCR analyses, Dr. Kevin Bittman for assistance with the analyses using the XF24 instrumentation, Ms. Amy Kugath for technical assistance, in particular with zebrafish husbandry, and members of the Balice-Gordon lab for helpful discussions.
###end p 125
###begin title 126
References
###end title 126
###begin article-title 127
Mitochondrial fragmentation in neurodegeneration.
###end article-title 127
###begin article-title 128
Mitochondria in neuroplasticity and neurological disorders.
###end article-title 128
###begin article-title 129
Energy metabolism in mammalian brain during development.
###end article-title 129
###begin article-title 130
A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine.
###end article-title 130
###begin article-title 131
Defects of electron transfer flavoprotein and electron transfer flavoprotein ubiquinone oxidoreductase: glutaric acidemia type II.
###end article-title 131
###begin article-title 132
A new iron-sulfur flavoprotein of the respiratory chain. A component of the fatty acid beta oxidation pathway.
###end article-title 132
###begin article-title 133
Subunit structure of electron transfer flavoprotein.
###end article-title 133
###begin article-title 134
Fatty acid oxidation disorders.
###end article-title 134
###begin article-title 135
D,L-3-hydroxybutyrate treatment of multiple acyl-CoA dehydrogenase deficiency (MADD).
###end article-title 135
###begin article-title 136
Oral sodium 3-hydroxybutyrate, a novel adjunct to treatment for multiple acyl-CoA dehydrogenase deficiency.
###end article-title 136
###begin article-title 137
###xml 53 62 <span type="species:ncbi:7955">zebrafish</span>
Neuromuscular synaptogenesis in wild-type and mutant zebrafish.
###end article-title 137
###begin article-title 138
A perfect message: RNA surveillance and nonsense-mediated decay.
###end article-title 138
###begin article-title 139
Large-scale deletion and point mutations of the nuclear NDUFV1 and NDUFS1 genes in mitochondrial complex I deficiency.
###end article-title 139
###begin article-title 140
###xml 33 41 <span type="species:ncbi:9606">children</span>
Isolated complex I deficiency in children: clinical, biochemical and genetic aspects.
###end article-title 140
###begin article-title 141
Respiratory chain complex I deficiency.
###end article-title 141
###begin article-title 142
###xml 110 118 <span type="species:ncbi:9606">patients</span>
Decreased fatty acid beta-oxidation in riboflavin-responsive, multiple acylcoenzyme A dehydrogenase-deficient patients is associated with an increase in uncoupling protein-3.
###end article-title 142
###begin article-title 143
###xml 26 29 <span type="species:ncbi:9606">man</span>
###xml 34 39 <span type="species:ncbi:10090">mouse</span>
Mitochondrial diseases in man and mouse.
###end article-title 143
###begin article-title 144
###xml 18 27 <span type="species:ncbi:7955">zebrafish</span>
Loss of Hspa9b in zebrafish recapitulates the ineffective hematopoiesis of the myelodysplastic syndrome.
###end article-title 144
###begin article-title 145
How mitochondria produce reactive oxygen species.
###end article-title 145
###begin article-title 146
Bioenergetics and the formation of mitochondrial reactive oxygen species.
###end article-title 146
###begin article-title 147
Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation.
###end article-title 147
###begin article-title 148
Understanding the Warburg effect: the metabolic requirements of cell proliferation.
###end article-title 148
###begin article-title 149
###xml 101 110 <span type="species:ncbi:7955">zebrafish</span>
BrdU-, neuroD (nrd)- and Hu-studies reveal unusual non-ventricular neurogenesis in the postembryonic zebrafish forebrain.
###end article-title 149
###begin article-title 150
###xml 37 46 <span type="species:ncbi:7955">zebrafish</span>
Anatomy of neurogenesis in the early zebrafish brain.
###end article-title 150
###begin article-title 151
PPAR gamma: an essential role in metabolic control.
###end article-title 151
###begin article-title 152
###xml 102 105 <span type="species:ncbi:10116">rat</span>
Differential expression of peroxisome proliferator-activated receptor-alpha, -beta, and -gamma during rat embryonic development.
###end article-title 152
###begin article-title 153
###xml 104 107 <span type="species:ncbi:10116">rat</span>
Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS.
###end article-title 153
###begin article-title 154
Peroxisome proliferator-activated receptor gamma-mediated regulation of neural stem cell proliferation and differentiation.
###end article-title 154
###begin article-title 155
###xml 18 27 <span type="species:ncbi:7955">zebrafish</span>
Patterning of the zebrafish retina by a wave of sonic hedgehog activity.
###end article-title 155
###begin article-title 156
###xml 37 46 <span type="species:ncbi:7955">Zebrafish</span>
Stat3 Controls Cell Movements during Zebrafish Gastrulation.
###end article-title 156
###begin article-title 157
Control of respiration and ATP synthesis in mammalian mitochondria and cells.
###end article-title 157
###begin article-title 158
Multiple acyl-CoA dehydrogenation deficiency (glutaric aciduria type II), congenital polycystic kidneys, and symmetric warty dysplasia of the cerebral cortex in two newborn brothers. II. Morphology and pathogenesis.
###end article-title 158
###begin article-title 159
Glutaric acidemia type II: neuroimaging and spectroscopy evidence for developmental encephalomyopathy.
###end article-title 159
###begin article-title 160
Neuroradiologic findings in glutaric aciduria type II.
###end article-title 160
###begin article-title 161
###xml 58 64 <span type="species:ncbi:9606">infant</span>
Symmetric hypoplasia of the temporal cerebral lobes in an infant with glutaric aciduria type II (multiple acyl-coenzyme A dehydrogenase deficiency).
###end article-title 161
###begin article-title 162
Electron transfer flavoprotein deficiency: functional and molecular aspects.
###end article-title 162
###begin article-title 163
###xml 33 41 <span type="species:ncbi:9606">patients</span>
Acylcarnitines in fibroblasts of patients with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency and other fatty acid oxidation disorders.
###end article-title 163
###begin article-title 164
Comparison of post-mortem urinary and vitreous humour organic acids.
###end article-title 164
###begin article-title 165
###xml 76 85 <span type="species:ncbi:7955">zebrafish</span>
Olig2+precursors produce abducens motor neurons and oligodendrocytes in the zebrafish hindbrain.
###end article-title 165
###begin article-title 166
###xml 43 48 <span type="species:ncbi:9606">human</span>
Growth inhibition and apoptosis induced in human leiomyoma cells by treatment with the PPAR gamma ligand ciglitizone.
###end article-title 166
###begin p 167
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 167
###begin p 168
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: Supported by NIH grant NS050524 to R. B.-G. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 168

